BRPI0718966B8 - composto, composição farmacêutica, inibidor plk1 e agente antitumoral - Google Patents

composto, composição farmacêutica, inibidor plk1 e agente antitumoral

Info

Publication number
BRPI0718966B8
BRPI0718966B8 BRPI0718966A BRPI0718966A BRPI0718966B8 BR PI0718966 B8 BRPI0718966 B8 BR PI0718966B8 BR PI0718966 A BRPI0718966 A BR PI0718966A BR PI0718966 A BRPI0718966 A BR PI0718966A BR PI0718966 B8 BRPI0718966 B8 BR PI0718966B8
Authority
BR
Brazil
Prior art keywords
lower alkyl
group
alkyl group
compound
pharmaceutical composition
Prior art date
Application number
BRPI0718966A
Other languages
English (en)
Inventor
Kawamura Mikako
Mitsuya Morihiro
Hashihayata Takashi
Satoh Yoshiyuki
Original Assignee
Banyu Pharma Co Ltd
Msd Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Banyu Pharma Co Ltd, Msd Kk filed Critical Banyu Pharma Co Ltd
Publication of BRPI0718966A2 publication Critical patent/BRPI0718966A2/pt
Publication of BRPI0718966B1 publication Critical patent/BRPI0718966B1/pt
Publication of BRPI0718966B8 publication Critical patent/BRPI0718966B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

composto, composição farmacêutica, inibidor plki e agente antitumoral a presente invenção se refere a um composto representado pela fórmula [i]: ou um sal ou éster farmaceuticamente aceitável deste, onde r1 e r2, que podem ser os mesmos ou diferentes, são cada, um átomo de hidrogênio, um átomo de halogênio, um grupo alquila baixo que podem ser substituídos, ou um grupo ciclopropila; r3 e r4, que podem ser os mesmos ou diferentes, são cada, um átomo de hidrogênio, um grupo alquila baixo substituído por nr,rb, um grupo heterocíclico alifático com 4- a 6- membros, um grupo alquila baixo substituído por um grupo heterocíclico alifático com 4- a 6- membros, um grupo heterocíclico aromático com 5- a 6- membros, ou um grupo alquila baixo substituído por um grupo heterocíclico aromático com 5- a 6- membros; e r5 é um átomo de hidrogênio, a grupo ciano, um átomo de halogênio, ou um grupo alquila baixo.
BRPI0718966A 2006-12-28 2007-12-20 composto, composição farmacêutica, inibidor plk1 e agente antitumoral BRPI0718966B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2006356575 2006-12-28
JP2006-356575 2006-12-28
JP2007-265783 2007-10-11
JP2007265783 2007-10-11
PCT/JP2007/075224 WO2008081910A1 (en) 2006-12-28 2007-12-20 Novel aminopyrimidine derivatives as plk1 inhibitors

Publications (3)

Publication Number Publication Date
BRPI0718966A2 BRPI0718966A2 (pt) 2014-01-07
BRPI0718966B1 BRPI0718966B1 (pt) 2020-11-17
BRPI0718966B8 true BRPI0718966B8 (pt) 2021-05-25

Family

ID=39588592

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0718966A BRPI0718966B8 (pt) 2006-12-28 2007-12-20 composto, composição farmacêutica, inibidor plk1 e agente antitumoral

Country Status (24)

Country Link
US (1) US7977336B2 (pt)
EP (2) EP2116543A4 (pt)
JP (1) JPWO2008081914A1 (pt)
KR (1) KR101481388B1 (pt)
CN (1) CN101573361B (pt)
AR (1) AR064619A1 (pt)
AU (1) AU2007340530B2 (pt)
BR (1) BRPI0718966B8 (pt)
CA (1) CA2668738A1 (pt)
CL (1) CL2007003758A1 (pt)
CO (1) CO6190523A2 (pt)
CR (1) CR10784A (pt)
EC (1) ECSP099324A (pt)
GT (1) GT200900124A (pt)
IL (1) IL198675A0 (pt)
MA (1) MA31109B1 (pt)
MX (1) MX2009004920A (pt)
NO (1) NO20092770L (pt)
NZ (1) NZ577273A (pt)
PE (1) PE20081845A1 (pt)
RU (1) RU2458062C2 (pt)
SV (1) SV2009003258A (pt)
TW (1) TW200835485A (pt)
WO (2) WO2008081910A1 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101679408B (zh) 2006-12-22 2016-04-27 Astex治疗学有限公司 作为fgfr抑制剂的双环杂环化合物
JP5442449B2 (ja) 2006-12-22 2014-03-12 アステックス、セラピューティックス、リミテッド 新規化合物
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
WO2010013633A1 (ja) * 2008-07-31 2010-02-04 萬有製薬株式会社 細胞のｒｂステイタス及びｐｌｋ１阻害剤に対する感受性を予測する方法
JP4489132B2 (ja) * 2008-08-22 2010-06-23 株式会社東芝 磁気記録媒体の製造方法
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
US8445674B2 (en) 2009-10-21 2013-05-21 Hoffmann-La Roche Inc Heterocyclyl compounds
PH12012500778A1 (en) 2009-10-30 2012-11-26 Janssen Pharmaceutica Nv IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS
UY33213A (es) 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
EP2463289A1 (en) 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
JP6115962B2 (ja) 2011-06-27 2017-04-19 ヤンセン ファーマシューティカ エヌ．ベー． １−アリール−４−メチル−［１，２，４］トリアゾロ［４，３−ａ］キノキサリン誘導体
EP2554544A1 (en) 2011-08-01 2013-02-06 Almirall, S.A. Pyridin-2(1h)-one derivatives as jak inhibitors
MX342326B (es) 2011-09-27 2016-09-26 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante.
WO2014001314A1 (en) 2012-06-26 2014-01-03 Janssen Pharmaceutica Nv Combinations comprising pde 2 inhibitors such as 1-aryl-4-methyl- [1,2,4] triazolo [4,3-a] quinoxaline compounds and pde 10 inhibitors for use in the treatment of neurological or metabolic disorders
AU2013289284B2 (en) 2012-07-09 2017-03-30 Janssen Pharmaceutica Nv Inhibitors of phosphodiesterase 10 enzyme
US9921222B2 (en) 2012-07-31 2018-03-20 Crown Bioscience, Inc. (Taicang) Histological markers for identifying non-small cell lung carcinoma patients for treatment with an anti-EGFR drug
WO2014046617A1 (en) * 2012-09-19 2014-03-27 Agency For Science, Technology And Research Compositions and methods for treating cancer
EP3194367B1 (en) 2014-09-17 2021-08-18 Boehringer Ingelheim International GmbH Tetrahydroisoquinoline derivatives and pharmaceutical compositions useful for the treatment of obesity and diabetes
US20230190717A1 (en) * 2017-04-10 2023-06-22 City Of Hope P38 gamma inhibitors and method of use thereof
CN114269742B (zh) * 2019-07-10 2024-07-16 常州千红生化制药股份有限公司 作为治疗剂的4-(咪唑并[1,2-a]吡啶-3-基)-N-(吡啶基)嘧啶-2-胺的衍生物
EP4003992A1 (en) * 2019-07-24 2022-06-01 Merck Patent GmbH 4-(imidazo[1,2-a]pyridin-3-yl) -pyrimidine derivatives
CN112592318B (zh) * 2020-12-12 2022-05-03 贵州医科大学 2-(4-甲氨酰基)苯胺基-4-氨基嘧啶衍生物及应用
WO2024071401A1 (ja) 2022-09-29 2024-04-04 公益財団法人がん研究会 Ｐｌｋ１キナーゼ活性化による染色体制御破綻が誘導するがん細胞増殖抑制を創薬概念とする医薬のスクリーニング方法
CN119318874B (zh) * 2024-12-18 2025-04-15 淄博凯美可工贸有限公司 一种节能型复合脱硫剂的制备方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5223608A (en) 1987-08-28 1993-06-29 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
FI95708C (fi) 1988-10-31 1996-03-11 Eisai Co Ltd Analogiamenetelmä 1,4-diatsepiinijohdannaisen ja sen farmaseuttisesti sopivan suolan valmistamiseksi
JPH045029A (ja) 1990-04-23 1992-01-09 Bridgestone Corp 空気入りタイヤ
DK0547165T3 (da) 1990-09-28 2000-03-27 Smithkline Beecham Corp Fremgangsmåde til fremstilling af vandopløselige camptothecinanaloger såvel som forbindelserne 10-hydroxy-11-C(1-6)-alkoxyc
US5243050A (en) 1990-12-20 1993-09-07 North Carolina State University Alkylpyridone DE ring intermediates useful for the manufacture of camptothecin and camptothecin analogs
US5162532A (en) 1990-12-20 1992-11-10 North Carolina State University Intermediates and method of making camptothecin and camptothecin analogs
US5191082A (en) 1990-12-20 1993-03-02 North Carolina State University Camptothecin intermediate and method of making camptothecin intermediates
US5200524A (en) 1990-12-20 1993-04-06 North Carolina State University Camptothecin intermediates and method of making same
US5247089A (en) 1990-12-20 1993-09-21 North Carolina State University Method of making intermediates useful for the manufacture of camptothecin and camptothecin analogs
KR100335584B1 (ko) 1992-10-28 2002-11-29 제넨테크, 인코포레이티드 혈관내피세포성장인자에대한길항제
JP3025602B2 (ja) 1993-05-21 2000-03-27 デビオファーム エス．アー． 光学的に高純度なシス−オキザラート（トランス−ｌ−１，２−シクロヘキサンジアミン）白金（ＩＩ）錯体の製造方法
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
CA2222231A1 (en) 1995-06-07 1996-12-19 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth of tumors
JP3154399B2 (ja) 1996-07-04 2001-04-09 デビオファーム エス．アー． 白金化合物の製造方法
US6610697B1 (en) * 1999-11-10 2003-08-26 Ortho-Mcneil Pharmaceutical, Inc. Substituted 2-aryl-3-(heteroaryl)-imidazo[1,2-a]pyrimidines, and related pharmaceutical compositions and methods
US6703508B2 (en) 2000-12-04 2004-03-09 Sepracor, Inc. Methods for the stereoselective synthesis of substituted piperidines
CA2450555A1 (en) 2001-06-25 2003-01-03 Merck & Co., Inc. (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds
CA2455181C (en) 2001-08-01 2010-04-06 Merck & Co., Inc. Benzimidazo[4,5-f]isoquinolinone derivatives
UA80296C2 (en) 2002-09-06 2007-09-10 Biogen Inc Imidazolopyridines and methods of making and using the same
WO2004043936A1 (ja) 2002-11-14 2004-05-27 Kyowa Hakko Kogyo Co., Ltd. Ｐｌｋ阻害剤
AU2005225471B2 (en) 2004-03-26 2011-05-12 Methylgene Inc. Inhibitors of histone deacetylase
CA2577947A1 (en) * 2004-08-31 2006-03-09 Banyu Pharmaceutical Co., Ltd. Novel substituted imidazole derivative

Also Published As

Publication number Publication date
CN101573361A (zh) 2009-11-04
AU2007340530B2 (en) 2012-09-13
RU2458062C2 (ru) 2012-08-10
EP2116543A1 (en) 2009-11-11
EP2114942A4 (en) 2010-09-08
SV2009003258A (es) 2010-08-23
CO6190523A2 (es) 2010-08-19
RU2009128966A (ru) 2011-02-10
BRPI0718966A2 (pt) 2014-01-07
KR20090092822A (ko) 2009-09-01
AR064619A1 (es) 2009-04-15
CN101573361B (zh) 2012-05-30
EP2114942A1 (en) 2009-11-11
EP2114942B1 (en) 2012-10-31
WO2008081914A1 (ja) 2008-07-10
PE20081845A1 (es) 2008-12-27
NO20092770L (no) 2009-09-25
AU2007340530A1 (en) 2008-07-10
CR10784A (es) 2009-09-16
BRPI0718966B1 (pt) 2020-11-17
US20080305081A1 (en) 2008-12-11
MX2009004920A (es) 2009-05-21
GT200900124A (es) 2010-11-03
MA31109B1 (fr) 2010-01-04
CL2007003758A1 (es) 2008-07-04
WO2008081910A1 (en) 2008-07-10
EP2116543A4 (en) 2010-09-08
IL198675A0 (en) 2010-02-17
TW200835485A (en) 2008-09-01
CA2668738A1 (en) 2008-07-10
KR101481388B1 (ko) 2015-01-12
NZ577273A (en) 2011-03-31
ECSP099324A (es) 2009-06-30
JPWO2008081914A1 (ja) 2010-04-30
US7977336B2 (en) 2011-07-12

Similar Documents

Publication Publication Date Title
ECSP099324A (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
BR122017028096B8 (pt) composto, composição farmacêutica, e, uso do composto
BRPI0821653B8 (pt) composto de piridina substituída com anel heterocíclico e grupo fosfonoximetila ou um sal do mesmo, composição farmacêutica compreendendo-os e uso dos mesmos para tratar uma doença fungíca
SI2091948T1 (sl) Novi inhibitorji glutaminil ciklaze
UA109525C2 (xx) Алкіламідна сполука і її застосування
UA117800C2 (uk) Похідні урацилу або тиміну для лікування гепатиту с
BRPI0412347A (pt) 2-aminofenil-4-fenilpiridinas como inibidores de quinase
BRPI1011683B8 (pt) derivados de isoquinolina substituída, suas composições farmacêuticas e seus usos
GT200600134A (es) Compuestos novedosos de derivados de aminosulfonilo
BR112013010552A2 (pt) derivado de piridina e agente medicinal
BRPI0814065B8 (pt) derivados de alcoóis de 1-fenil-2-piridinil alquila como inibidores da fosfodiesterase
NO20073791L (no) Pyrazolylaminopyridinderivater anvendbare som kinaseinhibitorer
EA201001683A1 (ru) Производные фенил- или пиридинилзамещенных индазолов
BR112014001801A2 (pt) indazóis
PH12014501283A1 (en) 4`-azido, 3``-fluoro substituted nucleoside derivatives as inhibitors of hcv rna replication
UY30897A1 (es) Derivados de pentafluorotiobenzamidoacetonitrilo, composiciones conteniéndolos y aplicaciones
EA201390163A1 (ru) Гетеробициклические производные в качетстве ингибиторов hcv
UA94606C2 (ru) Производные тиоксантина, композиция, которая их содержит, и их применение в терапии
JO3261B1 (ar) مشتق بيريدين أحادي الحلقة
NO20085212L (no) Nye pyridinanaloger
BR122018070508B8 (pt) derivados de arilamida triazol-substituída e seu uso
UA99485C2 (ru) Хиназолиндионовые производные, их получение и их применение в терапии
BRPI0408353A (pt) composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto
MX2010000658A (es) Derivados de pirimidina 934.
BR112012014058A8 (pt) Derivados de 3,4,4a,10b- tetraidro-1h- tiopirano[4,3-c]isoquinolina

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: MSD K.K. (JP)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 17/11/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/12/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF